We’re excited to share that Elektroniktidningen (ETN) has published an article about Bioelectrix and the bioelectronic technology behind our wound care solution ⚡️ The piece highlights how controlled direct current stimulation can support the healing process
Bioelectrix is developing a new medical device to actively accelerate wound healing. The technology itself is important, but in wound care, strong technology is not enough. For a solution to
Bioelectrix has been selected for the CO-AX Accelerator at Sahlgrenska Science Park, joining a cohort of health innovators shaping the next generation of healthcare solutions. As part of the program, Bioelectrix
Bioelectrix is pleased to announce the appointment of Jan Hörling as our new Chair of the Board. Jan joins Bioelectrix at an exciting time as we continue to strengthen our strategy, build momentum,
Bioelectrix has been selected as one of eight Nordic deep-tech teams in the REACH 2025–26 cohort, a Silicon Valley–based incubator program run by Nordic Innovation House to accelerate the commercialisation
🇩🇪 Back from Germany — and energized about what’s ahead for Bioelectrix ⚡️ Bioelectrix recently traveled to Germany as part of a delegation focused on strengthening cross-border collaboration in healthcare innovation.
How we are turning groundbreaking bioelectronics research into the future of advanced wound care. Our story began in Germany 🇩🇪 at the University of Freiburg, where we combined expertise in
Chalmers Ventures invests in Bioelectrix – groundbreaking technology to treat hard-to-heal wounds Bioelectrix is a new portfolio company at Chalmers Ventures. The company is taking on a global health problem—hard-to-heal